The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom

References

• ema.europa.eu. [Internet] London: European Medicines Agency; July 2014 [cited Jan 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2014/07/WC500169890.pdf
   Google Scholar
• European Medicines Agency; July 2014 [cited Jan 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2014/07/WC500169714.pdf
   Google Scholar
• Richardson M, Lass FC. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14:5–24.
   PubMed Web of Science ®Google Scholar
• Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J Med Res. 2014;139:195–204.
   PubMed Web of Science ®Google Scholar
• Bitar D, Lortholary O, Le Strat Y, et al. Population-based analysis of invasive fungal infections, France, 2001–2010. Emerg Infect Dis. 2014;20:1149–1155.
   PubMed Web of Science ®Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–366.
   PubMed Web of Science ®Google Scholar
• Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect Dis. 2012;54:S23–S34.
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–653.
   PubMed Web of Science ®Google Scholar
• Jeong SJ, Lee JU, Song YG, et al. Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis. Mycoses. 2015;58:746–752.
   PubMed Web of Science ®Google Scholar
• von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995;62:341–347.
   PubMed Web of Science ®Google Scholar
• Ceesay MM, Sadique Z, Harris R, et al. Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK. J Antimicrob Chemother. 2015;70:1175–1181.
   PubMed Web of Science ®Google Scholar
• Dodds AE, Drew R, Johnson M, et al. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacotherapy. 2012;32:890–901.
   PubMed Web of Science ®Google Scholar
• Huijskens EGW, Koopmans M, Palmen FMH, et al. The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia. J Med Microbiol. 2014;63:441–452.
   PubMed Web of Science ®Google Scholar
• Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013;98:492–504.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006;43:S3–S14.
   Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118:1216–1224.
   PubMed Web of Science ®Google Scholar
• Denning DW, Perlin DS, Muldoon EG, et al. Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities. Emerging Infect Dis. 2017;23:177–183.
   PubMed Web of Science ®Google Scholar
• medicines.org.uk. [Internet] Middlesex: emc; Nov 2017 [cited Feb 2018]. Available from: https://www.medicines.org.uk/emc/medicine/559/SPC/Fungizone±50mg±Powder±for±Sterile±Concentrate
   Google Scholar
• medicines.org.uk. [Internet] Middlesex: emc; Jan 2017 [cited Feb 2018]. Available from: https://www.medicines.org.uk/emc/product/5407
   Google Scholar
• medicines.org.uk. [Internet] Middlesex: emc; Jul 2016 [cited Feb 2018]. Available from: https://www.medicines.org.uk/emc/product/2226
   Google Scholar
• medicines.org.uk. [Internet] Middlesex: emc; Aug 2017 [cited Feb 2018]. Available from: https://www.medicines.org.uk/emc/product/5914
   Google Scholar
• medicines.org.uk. [Internet] Middlesex: emc; Apr 2017 [cited Dec 2017]. Available from: https://www.medicines.org.uk/emc/medicine/1236
   Google Scholar
• ec.europa.eu. [Internet] London: European Commission; 2005 [cited Feb 2018]. Available from: http://ec.europa.eu/health/documents/community-register/2005/200503299473/anx_9473_en.pdf
   Google Scholar
• ema.europa.eu. [Internet] London: European Medicines Agency; 2015 [cited Mar 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002734/WC500196128.pdf
   Google Scholar
• accessdata.fda.gov. [Internet] US: Food and Drug Administration; Mar 2015 [cited Feb 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf
   Google Scholar
• accessdata.fda.gov. [Internet] US: Food and Drug Administration; Oct 2008 [cited Mar 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050740s016lbl.pdf
   Google Scholar
• accessdata.fda.gov. [Internet] US: Food and Drug Administration; Feb 2005 [cited Mar 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21227s015lbl.pdf
   Google Scholar
• accessdata.fda.gov. [Internet] US: Food and Drug Administration; Nov 2015 [cited Mar 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf
   Google Scholar
• accessdata.fda.gov. [Internet] US: Food and Drug Administration; Feb 2015 [cited Mar 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021266s038,021267s047,021630s028lbl.pdf
   Google Scholar
• accessdata.fda.gov. [Internet] US: Food and Drug Administration; Apr 2012 [cited Mar 2018]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020083s048s049s050lbl.pdf
   Google Scholar
• aidsinfo.nih.gov. [Internet] US: US Department of Health and Human Services; Dec 2017 [cited Mar 2018]. Available from: https://aidsinfo.nih.gov/drugs/6/amphotericin-b/115/professional
   Google Scholar
• aidsinfo.nih.gov. [Internet] US: US Department of Health and Human Services; Dec 2017 [cited Mar 2018]. Available from: https://aidsinfo.nih.gov/drugs/6/amphotericin-b/117/professional
   Google Scholar
• ema.europa.eu. [Internet] London: European Medicines Agency; Oct 2015 [cited Mar 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002734/WC500196128.pdf
   Google Scholar
• accessdata.fda.gov. [Internet] US: Food and Drug Administration; Mar 2015 [cited Jan 2019]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf
   Google Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–769.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–837.
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemoth. 2006;50:2009–2015.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Selleslag D, Heinz W, et al. A comparison of the safety profiles of isavuconazole vs voriconazole in the Phase 3 SECURE study in patients with invasive mould infections. Poster EP018 presented at 25th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Congress, Copenhagen, Denmark, April 25–28, 2015.
   Google Scholar
• Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69:1162–1176.
   PubMed Web of Science ®Google Scholar
• Harrington R, Lee E, Yang H, et al. Cost-effectiveness analysis of isavuconazole vs. voriconazole as first-line treatment for invasive aspergillosis. Adv Ther. 2017;34:207–220.
   PubMed Web of Science ®Google Scholar
• Floros L, Kuessner D, Posthumus J, et al. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. BMC Infect Dis. 2019;19:134.
   PubMed Web of Science ®Google Scholar
• Bagshaw E, Carotti A, Blackney M, et al. The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Italy: Economic evaluation of the phase III vital study and FungiScope matched case-control analysis, in Poster presented at: 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France, March 26–29, 2017.
   Google Scholar
• Bagshaw E, Blackney M, Heimann SM, et al. The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Germany: economic evaluation of the phase III VITAL study and FungiScope matched case-control analysis, in Poster presented at: 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 22–25, 2017.
   Google Scholar
• Bagshaw E, Kuessner D, Posthumus J, et al. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK. Future Microbiol. 2017;12:515–525.
   PubMed Web of Science ®Google Scholar
• Bagshaw E, Enoch DA, Blackney M, et al. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK. Future Microbiol. 2018;13:1283–1293.
   PubMed Web of Science ®Google Scholar
• digital.nhs.uk. [Internet] UK: NHS Digital; 2016/2017 [cited Feb 2019]. Available from: https://files.digital.nhs.uk/publication/7/d/hosp-epis-stat-admi-diag-2016-17-tab.xlsx
   Google Scholar
• Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007;78:532–539.
   PubMed Web of Science ®Google Scholar
• Bower H, Bjorkholm M, Andersson T-L, et al. Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life. Blood Cancer J. 2016;6:e390.
   PubMed Web of Science ®Google Scholar
• Leunis A, Redekop WK, Uyl-de Groot CA, et al. Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. Eur J Haematol. 2014;93:198–206.
   PubMed Web of Science ®Google Scholar
• nice.org.uk. [Internet] UK: National Institute for Health and Care Excellence; Apr 2013 [cited Jan 2019]. Available from: https://www.nice.org.uk/process/pmg9/chapter/the-reference-case#discounting
   Google Scholar
• Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503–509.
   PubMed Web of Science ®Google Scholar
• accessdata.fda.gov. [Internet] US: Center For Drug Evaluation And Research; July 2014 [cited Jan 2019]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf
   Google Scholar
• ema.europa.eu. [Internet] London: European Medicines Agency; July 2015 [cited Feb 2018]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002734/WC500196130.pdf
   Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–1402.
   PubMed Web of Science ®Google Scholar
• assets.publishing.service.gov.uk. [Internet] UK: Department of Health; 2016 [cited Jan 2019]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/577083/Reference_Costs_2015-16.pdf
   Google Scholar
• medicines.org.uk. [Internet] Middlesex: emc; July 2018 [cited Jan 2019]. Available from: https://www.medicines.org.uk/emc/product/5388/smpc
   Google Scholar
• medicines.org.uk. [Internet] Middlesex: emc; Jul 2018 [cited Jan 2019]. Available from: https://www.medicines.org.uk/emc/product/3435/smpc
   Google Scholar
• Fluckiger U, Marchetti O, Bille J, et al. Treatment options of invasive fungal infections in adults. Swiss Med Weekly. 2006;136:447–463.
   PubMed Web of Science ®Google Scholar
• Horn D, Goff D, Khandelwal N, et al. Hospital resource use of patients receiving isavuconazole versus voriconazole for invasive mold infections in the phase III SECURE trial. J Med Econ. 2016;19:728–734.
   PubMed Web of Science ®Google Scholar
• Xhaard A, Lanternier F, Porcher R, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003–2008). Clin Microbiol Infect. 2012;18:E396–E400.
   PubMed Web of Science ®Google Scholar
• Leenders A, Daenen S, Jansen RLH, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103:205–212.
   PubMed Web of Science ®Google Scholar
• Matched-case analysis of primary mucormycosis patients from isavuconazole study 9766-CL-0103/WSA-CS-003 to patients from FungiScope registry database. 2014.
   Google Scholar
• medicines.org.uk. [Internet] Middlesex: emc; 2018 [cited Jan 2019]. Available from: https://www.medicines.org.uk/emc/product/1022/smpc
   Google Scholar
• medicinescomplete.com. [Internet] UK: Medicines Complete; 2019 [cited Jan 2019]. Available from: https://about.medicinescomplete.com/#/browse/bnf
   Google Scholar
• Curtis L, Burns A, [Internet] UK: PSSRU; 2017 [cited Jan 2019]. Available from: https://kar.kent.ac.uk/65559/40/65559_rep_UCR-2017-v13finalKAR.pdf
   Google Scholar
• Patterson TF, Thompson GR, 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–e60.
   PubMed Web of Science ®Google Scholar
• Keirns J, Desai A, Kowalski D, et al. QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization. Clin Pharmacol Ther. 2017;101:782–790.
   PubMed Web of Science ®Google Scholar
• Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. IDR. 2016;9:291–300.
   Google Scholar
• Townsend R, Desai A, Azie N, et al. Drug interaction profiles of isavuconazole, voriconazole and posaconazole with immunosuppressants metabolized by CYP4503A4 (CYP3A4). Mycoses. 2015;58:218–219.
   Web of Science ®Google Scholar
• Weidlich D, Hicks M, Floros L, et al. Estimating the budget and clinical impact of introducing isavuconazole for the treatment of patients with possible invasive aspergillosis in the United Kingdom. 2018, Poster presented at ISPOR Europe, 10–14 Nov, 2018.
   Google Scholar
• Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6:76–85.
   PubMed Web of Science ®Google Scholar